A few days ago, the medical policy information platform "Hongchen Medical Valley" revealed the suspected "Qinghai Province 2019 Centralized Procurement and Implementation Plan for Drugs" (hereinafter referred to as the "Plan").
Qinghai follow up 4+7
The "Plan" shows that Qinghai plans to implement centralized procurement in the province. The procurement catalog not only contains 4+7 selected products, but is divided into three groups:
The first group: passed the consistency evaluation drug and the "4+7 national talks won the bidding product" catalog.
The second group: drugs that are purchased in large quantities and high in value. However, the current price is linked to the Internet, and the reduction needs to reach 30% or more to win the bid.
The third group: the basic large infusion group. From the perspective of the plan, the characteristic of this group is that the packaging materials are grouped "very carefully" (signs of manual operation are obvious), including "glass bottles, plastic bottles, soft bags (including soft bags, double valves, soft bags). The four types of packaging materials (bags, double valves, double-layer sterile) and vertical polypropylene infusion bags are purchased in quantity.
Medical insurance advance payment, starting in June
Qinghai’s "Plan" stated that it adopts a negotiated procurement method that is in line with the bidding companies. Each type of medicine is shortlisted and one is selected. The purchase volume shall not be less than 80% of the actual drug use volume in 2018, which shall be reported to the planned purchase volume for allocation.
The medical insurance fund pays the working capital in advance to the medical institution in three installments in accordance with the purchase amount agreed in the contract.
The first prepayment ratio of 30% will be completed after the purchase and sales contract is signed; the second prepayment ratio of 50% will be completed within 6 months of the signing of the purchase and sales contract; the third prepayment ratio of 20% will be completed within 9 months of the signing of the purchase and sales contract.
plans to start in June 2019.
Multi-location linkage, there is no suspense in the whole country
Qinghai’s volume procurement plan is exactly the same as the national version. Since the beginning of 4+7 implementation, the industry has predicted that more places will follow up — 4+7 is a pioneer and will inevitably form a national push. However, in terms of the current speed and quantity of follow-ups outside of the 11 cities, it still exceeds expectations. At present, including Qinghai, five provinces and cities have indicated that they will follow 4+7.
On May 14, the Fujian Pharmaceutical Procurement Center organized 4+7 selected companies and some commercial companies to hold a symposium, and announced the implementation plan for the province’s linkage to follow up on the 4+7 results. The linkage covers all public medical institutions in the province. The varieties are the first batch of 4+7 varieties.
On April 25, the Taiyuan Medical Insurance Management Service Center issued a notice stating that according to the requirements of the Provincial Medical Insurance Bureau, Taiyuan intends to follow up the 4+7 urban drug concentration in the city’s administrative area with various public medical institutions at all levels. Procurement work.
Recently, it was reported that Tangshan City and Qinhuangdao City Medical Insurance Bureau held a meeting to initiate the 4+7 linkage between the two cities to study specific rules.
In fact, there is no suspense about the promotion of mass procurement nationwide. It is just a matter of time. Many leaders have publicly expressed their opinions on this. Recently, at the national medical reform work video conference held on May 17, The leaders reiterated: timely perfect and comprehensively launch the nationally organized drug centralized procurement system.